2019 Newsletter
XXXIV Edition

William Guy Forbeck Research Foundation

WGFRF.org
William Guy Forbeck Research Foundation

Cancer's Leading Thinkers. Together in one room.

Contents



Are We Making Progress?

The death rate from cancer in the USA has declined steadily over the past two decades, according to annual statistics reported by the American Cancer Society. As of 2015, the cancer death rate for men and women (combined) had fallen by 26% from its peak in 1991. This decline translates to nearly 2.4 million deaths averted during this period. Three factors have contributed to the decline in mortality associated with cancer: a reduction in smoking; better detection of the disease; and an improvement in the treatment regimens that have been developed and tailored for different cancers.

Cancer has now fallen behind cardiovascular disease as the major 'killer' in the USA. It is now the number two cause of death. However, the overall figure somewhat flatters the facts. The reduction in smoking is a 'once only phenomenon' when considered in relation to a statistical analysis of cancer rates in the community. It is doubtful that any other single change in behavior will have such a major effect on cancer rates in the future. This means that in coming years a similar reduction in the number of cancer cases is unlikely. Although, today tobacco remains responsible for nearly three in ten cancer deaths, getting the hard-core smoker to stop becomes increasingly difficult. Therefore, the impact that smoking has on cancer statistics is likely to fall over time.

It is clear that more needs to be done. It has been estimated that over 1.7 million new cancer cases were diagnosed in the USA in 2018 and approximately 600,000 deaths were projected in the same year. Taking smoking out of the equation, what can now be done to improve both the diagnosis and treatment of cancer?

It is the job of the pharmaceutical industry to develop and test better drugs. They must replace the old types of anti-cancer drugs that, as a generalization, were designed to kill rapidly dividing cells. We have now entered the world of 'designer cancer drugs'. This has only been possible through the extensive research that has been undertaken by both academia and industry to identify new molecular targets. These programs have only been partially successful when considering the amount of money that has been spent by the industry. Yet, as a whole, only a limited number of drugs have emerged from this developmental process. Nevertheless, progress has been made in the treatment of various cancers, such as some forms of skin cancer and leukemia.

(continued on page 2)

Are We Making Progress?

...continued

More work is needed, however, to understand how the biochemical pathways within cells interact and how to prevent cells from developing ways of escaping resistant 'designer' drugs.

While the pharmaceutical industry has been adept at developing drugs, academia has driven research in a different direction. Many academics have focused on the manipulation of the patient's immune system to attack the cancer cells within his or her body. Antibodies are used to selectively recognize and kill cancer cells. In an alternative approach, elements of the cellular part of the immune system have been genetically engineered to target and kill the tumor cells. Amazing results have been seen in children and adults with specific forms of leukemia. Whether similar approaches will work against the more common solid tumors remains to be seen.

The genetic manipulation of a patient's own immune system is truly a 21st century therapy, but it comes at a very heavy cost for both industry and the health authorities.

An alternative, but potentially fruitful approach to cancer treatment, is to personalize therapy. Rather than giving drugs carte blanche to a patient with a specific cancer type, a sample of the patient's cells (biopsy) is tested in the laboratory to determine which mixtures of drugs are most effective at killing the patient's tumor cells. The patient then receives a tailored cocktail of anti-cancer drugs to which his or her tumore is susceptible. The Foundation has been instrumental in setting up an organization in the US to further this approach to cancer treatment.

As our search for safer and more effective drugs continues, we will need to address the increasing financial and technical challenges of medicine to ensure that our healthcare systems can cope. Just how much our healthcare systems can afford in order to bring new developments to the clinic in the future is a topic for another day. We play our part by ensuring we can cut the development process by ensuring that interactions on key topics are at the very best level and that young talented researchers are given every opportunity to explore their ideas and build the collaboration in today's ever increasing complex knowledge base.

Written by:
John T. Kemshead, PhD, FRCPath

The State of the Foundation

The Foundation is in a very exciting place right now. Over the course of 30 years, we have hosted an annual forum in November and more recently an annual scholar retreat in October. When asked for feedback from the participants, we commonly hear "I love these meetings!", or "These forums are extremely stimulating". Due to increased demands by the scientific community for more engagement, we have six meetings planned for 2019 and seven for 2020.

My interactions with the Forbeck Foundation has had a big impact on my scientific career and that of one of my post-doctoral fellow Olivier Ayrault who just published a paper in Cancer Cell, one of the top journals in Cancer Research .

- Martine F Roussel, PhD
St Jude Children's Research Hospital

One of the main changes we have made is that, although the scientific advisory board still picks one meeting topic that they feel is important to research now, all of the other meeting requests are coming from the scientific community. Forbeck Forums are regularly requested from the scientific community because they are different; an opportunity to really think outside the box, gather people from various disciplines to brainstorm. This is where the new ideas in the fight against cancer will originate; where scientists get excited again; form collaborations and continue to pave the way for progress.

With the increased programs, the Foundation needs to keep up with fundraising. We are able to grow comfortably thanks to a sound financial background in the Foundation. Please continue to support this endeavor. Now, more than ever, we would love for our benefactors to attend a meeting this year to see what they are supporting and to help us find others who will be interested in this undertaking.

Forbeck Forums:
Cancer Research throughout the Decades

This list does not include focus meetings and many other scientific events funded and organized by the Forbeck Foundation.

2019 – Cancer and Aging
2019 – Telomerase-Mediated Telomere Targeting in Cancer
2019 – DIPG Consensus Meeting
2019 – Leukemia stem cells, heterogeneity, and metabolism
2019 – 3D Chromosomal Architecture and Nuclear Topology
2018 – Cancer Predisposition
2018 – Tumor Microenvironment
2018 – Epigenetic Therapy
2018 – Metabolic Signaling and the Epigenome
2017 – MYC/RAS
2016 – Chromosomal Instability/Aneuploidy
2015 – Cancer Immunotherapy
2014 – Invasion and Metastasis
2013 – Resistance Mechanisms
2012 – Tumor Metabolism
2011 – Epigenetics
2010 – Cancer Genomics
2009 – The Biology and Treatment of Primary Brain Tumors
2008 - Immunotherapy and Breaking Tolerance
2007 – Micro RNA and Cancer
2006 – Stem Cells
2005 - Innovations in Imaging in Cancer Research
2004 - Molecular Targets in Pediatric Malignancies
2003 - DNA Damage and Cancer Susceptibility Syndromes
2002 - Cellular Senescence and Cancer
2001 - Differentiation as Cancer Therapy
2000 – Allogeneic Stem Cell Transplantation
1999 - Targeting Gene Therapy – A Reality?
1998 - Angiogenesis and Accessibility
1997 - Second Malignancies
1996 - Specific Simple Models to Clinical Disease
1995 - Apoptosis
1994 - Cell Cycle Checkpoints
1993 - Growth Factors
1992 - Gene Therapy and Tumor Vaccines
1991 - Dose Intensification in Pediatric Malignancies
1990 - Molecular Origins of Pediatric Embryonal Malignancies
1989 - Infectious Complications
1988 - Improved Drug Delivery to Brain Tumors
1987 - Reasons for Drug Failure
1986 - Tumor Progression and Differentiation
1985 - Neuroblastoma

For more information about these topics, please visit wgfrf.org.

2018 Forum Reviews

Metabolic Signaling

Julie-Aurore Losman, MD, PhD, Dana-Farber
Kathryn Wellen, PhD, University of Pennsylvania



On behalf of the attendees of the Forbeck Forum on Metabolic Signaling and the Epigenome, we would like to thank the Forbeck Foundation for organizing and sponsoring this exceptional meeting. We all feel that it was extremely useful and that the discussions that took place will have an important impact on our work. In fact, several collaborations have already begun based on discussions during the meeting.

Participants

Julie Aurore-Losman, MD, PhD - Dana-Farber Cancer Institute	Mei Kong, PhD - City of Hope
Nabeel Bardeesy, PhD - Massachusetts General Hospital	Jason Locasale, PhD - Duke University
Bryce Carey, PhD - Rockefeller University	Oliver G. McDonald, MD, PhD - Vanderbilt University
John Denu, PhD - University of Wisconsin	Jordan Meier, PhD - National Cancer Institute
Andrew Dillin, PhD - University of California, Berkeley	Joshua D. Rabinowitz - Princeton University
Lydia Finley, PhD - Memorial Sloan Kettering Cancer Center	Martine Roussel, PhD - St. Jude Children's Research Hospital
Christian Frezza, MSc, PhD - University of Cambridge	Paolo Sassone-Corsi, PhD - University of California, Irvine
Lucy Godley, MD, PhD - University of Chicago	Benjamin Tu, PhD - UT Southwestern
Russell Jones, PhD - McGill University	Karen Vousden, PhD - The Francis Crick Institute
William Kaelin, Jr. IV, MD - Dana-Farber Cancer Institute	Kathryn Wellen, PhD - University of Pennsylvania

Epigenetic Therapy

Jean-Pierre Issa, MD, Temple University
Stephen Baylin, MD, Johns Hopkins University
Peter Jones, PhD, Van Andel Research Institute



Epigenetic therapy refers to treatments aimed at changing the nature of cancer cells by manipulating the instructions that govern their cellular identity. Over the past few years, this field has led to many drugs that are being tested in clinical trials, some of which have made it all the way to FDA approval. The meeting focused on expanding these successes by understanding better how current therapies work, by discovering new ways to target epigenetics, and by designing therapy combinations that exploit the effects of the drugs on cellular identity and phenotypes. An emerging theme of the meeting was the effects of epigenetic therapies on the immune system, and on designing therapies based on therapeutic vulnerabilities created by mutations in epigenetic effectors, or by drugs that inactivate these effectors.

Participants

Stephen Baylin, MD - Johns Hopkins University	Matthew Lorincz, PhD - University of British Columbia
Shelley L. Berger, PhD - University of Pennsylvania Pearlman School of Medicine	Kenneth P. Nephew, PhD - Indiana University School of Medicine
Daniel De Carvalho, PhD - Princess Margaret Cancer Centre	Feyruz V. Rassool, PhD - University of Maryland
Lucy Godley, MD, PhD - University of Chicago	Charles Roberts, MD, PhD - St. Jude Children's Research Hospital
Kristian Helin - Biotech Research & Innovation Centre and University of Copenhagen	Padmanee Sharma, MD, PhD - MD Anderson Cancer Center
Jean Issa, MD - Temple University	Yang Shi, PhD - Harvard Medical School
Nada Jabado, MD, PhD - Research Institute of the McGill University Health Center	Ali Shilatifard, PhD - Northwestern, Feinberg School of Medicine
Peter Jones, PhD D.Sc - Van Andel Research Institute	Rugang Zhang, PhD - The Wistar Institute
Cigall Kadoch, PhD - Dana-Farber Cancer Institute	

Tumor Microenvironment

Rakesh K. Jain, PhD, Massachusetts General Hospital
Lisa M. Coussens, PhD, Knight Cancer Institute

The 2018 Forum on Tumor Microenvironment was chaired by Dr. Rakesh K. Jain of Massachusetts General Hospital and Harvard Medical School, and Dr. Lisa M Coussens from the Knight Cancer Institute at Oregon Health & Science University. The goal was to discuss the current state of the tumor microenvironment field, but also discuss approaches towards applying that knowledge to the development of effective and broadly applicable anti- cancer therapies for long-term management of disease.

Participants

Peter Carmeliet, MD, PhD - Center for Cancer Biology, VIB-KU Leuven Belgium	Elaine R. Mardis, PhD - Nationwide Children's Hospital
Lisa Coussens, PhD - Oregon Health & Science University	Daniela Quail, PhD - McGill University
David G. DeNardo, PhD - Washington University School of Medicine	Melodie Swartz, PhD - University of Chicago
Stephanie K. Dougan, PhD - Dana-Farber Cancer Institute	David Tuveson, MD, PhD - Cold Spring Harbor Laboratory
Mikala Egeblad - Cold Spring Harbor Laboratory	Matthew Vander Heiden, MD, PhD - Koch Institute at MIT
Ronald N. Germain, MD, PhD - NIAID, National Institute of Health	Jennifer Wargo, MD - MD Anderson Cancer Center
Richard O. Hynes, PhD - Koch Institute for Integrative Cancer Research at MIT	Irv Weissman, MD - Stanford University
Rakesh Jain, PhD - Massachusetts General Hospital	

Cancer Predisposition

Judy E. Garber, MD, MPH, Harvard University
John M. Maris, MD, University of Pennsylvania

The forum focused on the question of why individuals develop cancer. Experts from around the globe shared recent insights into the genetic basis of human cancer and how to use genetic information to prevent and/or treat pediatric and adult malignancies. Cancer is a genetic disease. Recent technologic advancements have revolutionized our insights into the genetic basis of cancer and is providing multiple opportunities to improve diagnosis, prevention and therapy.

There was enthusiastic agreement that the convened panel of international experts in cancer genetics should meet again and several concrete collaborations were established by the scholars with other scholars or more senior investigators.

What do I see developing in this field from this meeting? Novel strategies for cancer prevention, interception and therapy.

Participants

Stephen Chanock, MD - National Cancer Institute	David Malkin, MD, FRCPC - The Hospital for Sick Children
Olivier DeLattre - Institut Curie	John Maris, MD - Children's Hospital of Philadelphia
Douglas Easton, PhD - University of Cambridge	Yael Mosse, MD - Children's Hospital of Philadelphia
William Foulkes, PhD, M.B.B.S., B.Sc. - McGill University	Kenneth Offit, MD - Memorial Sloan Kettering Cancer Center
Judy Garber, MD, MPH - Dana-Farber Cancer Institute	Olopade Olufunmilayo, MD - University of Chicago
Elizabeth Jaffee, MD - Johns Hopkins University	Sharon Plon, MD, PhD - Baylor College of Medicine
Allison W. Kurian, MD, M.Sc. - Stanford University	Joshua B. Rubin, MD, PhD - Washington University
Mignon Loh - UCSF Benioff Children's Hospital	Uri Tabori, MD - The Hospital for Sick Children

"The meeting was a jam-packed 1.5 days of extremely interesting talks that linked metabolic changes in cancer to re-wiring of the genome, in this case, epigenome. While I was a bit out of my comfort zone dealing with the cancer side of things, it was clear that the links between metabolism and the epigenome were spot on."

- Andrew Dillin, PhD, University of California, Berkeley

2019 Forum Previews

2019 Scholar Retreat
Chad Pecot, MD from the UNC Lineberger Comprehensive Center, Chapel Hill, NC, will be chairing this years Retreat.

Each year Scholars are selected for each specific forum topic. Below are the topics that will be represented at this years scholar retreat.

2019	3D Chromosomal Architecture and Nuclear Topology
2018	Cancer Predisposition
2017	MYC/RAS
2016	Chromosomal Instability/Aneuploidy
2015	Cancer Immunotherapy

2019 is shaping up to be our biggest year yet. We have five Forums scheduled plus the Scholar Retreat and cannot wait to see the progress and collaborations that come out of each of these meetings.

We would love for you to attend a meeting this year. Please contact admin@wgfrf.org for more information and reserve your seat.

3D Chromosomal Architecture and Nuclear Topology

May 2nd - 5th, 2019


Ari Melnick, MD, Cornell Medical College
Jane Skok, PhD, New York University

The precise and detailed 3D organization of chromosomal and chromatin looping is just now being understood to play a fundamental role in regulation of gene expression, DNA repair, DNA replication and cell cycle. Disruption of nuclear topology is emerging as a potential new hallmark of cancer. For example, somatic mutation of the loop and boundary protein CTCF are prevalent in many types of cancer, as are mutations of the various proteins that make up or regulate the cohesin complex that plays a central role in architectural effects. In addition, there is a rapidly increasing body of evidence that somatic mutation of looping elements can drive development of cancer by either disrupting the location of large gene enhancer clusters, boundary elements, lncRNAs that strengthen looping, and binding affinity of regulatory DNA elements for proteins that drive specific 3D architectural features.

Leukemia Stem Cells, Heterogeneity, and Metabolism

September 12th - 15th, 2019



Martin Carroll, MD, University of Pennsylvania
Craig T. Jordan, PhD, University of Colorado
Aaron Schimmer, MD, PhD, Princess Margaret Cancer Centre

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a generally poor outcome. Despite the ability to achieve remission with aggressive chemotherapy, most patients relapse and ultimately succumb to their disease. Relapse disease is frequently due to chemoresistant leukemia stem cells (LSCs). Thus, new therapeutic approaches that are less toxic and better tolerated by older and frailer individuals are required. Moreover, new therapies that target the LSC population to induce cell death or promote their differentiation into more mature cells are required. The last few years have seen tremendous advances in our understanding of LSC biology and potential new therapies to target these cells. Therefore, we believe this is a critical time to convene a group of experts to synthesize new therapeutic directions. Thus, our proposed Forbeck conference will bring together a multi-disciplinary group of leading experts (basic scientists, translational scientists, and clinical trialists) to design compelling strategies for translational/clinical studies.

The objective will be to create a strategic plan for designing highly innovative and impactful strategies for improving AML therapy. Participants will include clinical investigators with expertise in AML to develop the novel clinical strategies and clinical trials, as well as laboratory/translational scientists to who will provide the biological and preclinical support for new therapies as well as to conduct correlative studies in the context of the clinical trials. Our goal is that this group, or at least a subset, will form a consortium that will work together in coming years to implement plans developed from the conference.

DIPG Consensus Meeting

October 3rd - 6th, 2019




Oren Becher, MD, Northwestern University
Cynthia Hawkins MD, PhD, The Hospital for Sick Kids

DIPG is a rare incurable childhood brain cancer. Unfortunately, the standard of care has not significantly improved in over 50 years with focal radiation being the norm. This is in stark contrast to the improved treatments for many other cancers like melanoma, lung cancer, kidney cancer, leukemia, and neuroblastoma.

A recent analysis of DIPG tumor tissue has identified some of the main genetic events that drive DIPG formation. This powerful piece of knowledge, along with other advances such as the development of model systems, and the increasing use of biopsies as part of the diagnostic workup for children with DIPG will eventually lead to effective therapies. This cannot be done however without foundations like the Forbeck Foundation. The Forbeck Foundation is world-renowned for supporting an innovative discussion forum where approximately 15 scientists, in an intimate setting, have the opportunity to discuss unpublished research results. Bringing together diverse experts together like this, to learn from and challenge each other, is an innovative approach that will no doubt yield real progress for DIPG. **This meeting was generously sponsored by the Kira Spedale Foundation.**

Telomerase-Mediated Telomere Targeting in Cancer

October 17th - 20th, 2019


Titia de Lange, PhD, Rockefeller University
Jerry W. Shay, PhD, UT Southwestern

As humans age, the ends of linear chromosomes, telomeres, become progressively shorter. Short telomeres elicit a DNA damage response that leads cells to stop dividing and under go senescence or apoptosis. This process inhibits the outgrowth of cancer cells that have undergone an abnormally high number of cell divisions. However, rare cancer cells can activate a cellular reverse transcriptase, telomerase, to reconstitute functional telomeres. Telomerase is absent in most normal tissues but is detected in the great majority of clinically detectable cancers. Thus, while telomerase is not oncogenic per se, it is almost universally required to permit the indefinite growth that occurs as part of cancer progression. Therefore, the inhibition of telomerase is an attractive target for cancer therapeutics. There have been several approaches to targeting telomerase in cancer in the past, but none have advanced to late-stage clinical trials. Thus, it is timely to review the progress and future directions for targeting telomerase in this Forbeck conference. Topics will include a discussion on why progress has been slow and how going forward this may change using new approaches. There will be discussions on human genetic disorders affecting telomeres, alternatives to telomerase in a subset of tumors and the role of senescence as an initial brake preventing premalignant cells from progressing to advanced cancers.

Cancer and Aging

November 7th - 10th, 2019


Steve Artandi, MD, PhD of Stanford University
Marcia Haigis, PhD of Harvard Medical School

In human adults, cancer is inextricably linked to the aging process. The incidence of most cancers increases exponentially beginning in the fifth and sixth decades of life. Diverse aspects of human aging have been proposed to contribute to this link between aging and cancer. New molecular insights into both the causes of human aging and the causes of human cancer provide an opportunity for a critical exchange of ideas between leaders in these two fields. Many stress and nutrient signaling pathways, including mTOR, RAS/Map Kinase transduction, p53 responses, insulin/growth factors, and cellular senescence regulate healthspan and lifespan, as well as cancer. DNA mutations, damage to DNA, and alterations in chromatin are emerging as a common hallmark of both normal human aging and drive the evolution of premalignant clones. Genetic analyses of centenarians and cancer-prone populations have resulted in a plethora of new information relevant for healthy aging and cancer prevention. We will also discuss recent findings regarding small molecule interventions, diet and caloric intake on longevity, healthy lifespan, and tumorigenesis. This meeting will enable a highly interactive exchange focused on the emerging intersection between the aging and cancer fields.

2018 Scholar Retreat in Review

This meeting was a Scholars' Retreat attended by scholars from four previous forums as well as five mentors who run the gamut from recently-appointed assistant professors to well-established full professors.

Each of the attendees presented their work-in-progress, which was discussed in detail by the entire group. The research topics that were covered included: cancer invasion and metastasis; cancer immunotherapy; chromosomal instability and aneuploidy; and targeting MYC and RAS. All four of these topics are areas of intense on-going research at the basic science, translational and clinical levels.

The Forbeck Scholars who attended this meeting are among the best and brightest young investigators in their respective fields and they are certain to make important scientific contributions in the coming years. The opportunity for them to discuss their work and career development in the intimate setting of the Forbeck Scholars Retreat is an invaluable experience that will help to propel their independent research careers. As a former scholar, I can personally attest to the benefit of this meeting when one is setting up their own lab, hiring people and applying for major grants for the first time. At the meeting, thanks to its format that emphasizes intense discussion, participants had the opportunity to start establishing personal connections that are sure to lead to future collaborations.

Julie-Aurore Losman, MD, PhD
Dana-Farber Cancer Institute

Forbeck Spring Scholar Awards 3D Chromosomal Architecture

Danfeng Cai, PhD
National Institutes of Health

Danfeng studies how the Yes-associated Protine (YAP), a transcriptional coactivator important for activating genes involved in cell proliferation and survival, re-organizes the 3D nuclear structure and promotes cancer malignancy.



Peter Ly, PhD
Ludwig Institute for Cancer Research

Peter's independent lab will explore how linear DNA sequence alterations can deregulate normal 3D architecture and function. Another area will focus on how nuclear topology dictates the spatiotemporal kinetics of chromothriptic DNA fragment repair into producing complex chromosomal structures.



Kathleen Xie, PhD
Dana-Farber Cancer Institute

Kathleen is taking a mechanistic cell biology approach to studying nuclear structure. Although the lab she has joined for postdoctoral research (David Pellman lab) is a leading expert in genomics and in vitro cell biology.

Sponsor A Scholar

Each year Forbeck Scholars are selected from an elite pool of up and coming scientists in the cancer research field to attend our four-year program. Your pledge of $1,000 each year (totaling $4,000) will directly support a Scholar's participation in the program. An individual scholar will be identified with your pledge. You will be invited to the Kick-Off Dinner at the Scholar Retreat with the scientists and receive (2) tickets to the Blue Jean Ball each year you sponsor. This is your chance to participate in cancer research!

Please contact admin@wgfrf.org for more information.

2019 Retreat Scholars

Consider sponsoring one of the remaining unsponsored scholars. You will receive an invitation to a special dinner with the participants, Blue Jean Ball Tickets and have the opportunity to follow the career of your scholar; you will also be acknowledged as a Sponsor in Forbeck publications. For more information please visit wgfrf.org/ways-to-give

2019 FORBECK SCHOLARS - SPRING
Danfeng Cai, PhD
National Institutes of Health

Peter Ly, PhD
Ludwig Institute for Cancer Research

Kathleen Xie, PhD
Dana-Farber Cancer Institute

2018 FORBECK SCHOLARS
Kristopher Bosse, MD
Children's Hospital of Philadelphia
Sponsored by: Norine Smyth

Vivian Chang, MD
University of California, Los Angeles

Junne Kamihara, MD, PhD
Dana-Farber Cancer Institute

Daniela Robles-Espinoza, PhD
Intl. Lab for Human Genome Research

2017 FORBECK SCHOLARS
Andrew Aguirre, MD, PhD
Dana- Farber Cancer Institute
Sponsored by: The Gage Family

Donita Brady, PhD
Unviersity of Pennsylvania
Sponsored by: The Bates Foundation

W. Clay Gustafson, MD, PhD
University of California San Francisco
Sponsored by: Anne Lehman

Mara Sherman, PhD
Oregon Health & Science University
Sponsored by: The Ross Foundation

2016 FORBECK SCHOLARS
Uri Ben-David, PhD
Broad Institute
Sponsored by: Linda Tonge

Lilian Kabeche, PhD
Massachusetts General Hospital

Mia Levine, PhD
University of Pennsylvania

Stefano Santaguida, PhD
Massachusetts Inst of Technology
Sponsored by: Nancy Lehman

Jason Sheltzer, PhD
Cold Spring Harbor Laboratory

Neil Umbreit, PhD
Dana-Farber Cancer Institute

2015 FORBECK SCHOLARS
Esra Akbay, PhD
Dana-Farber Cancer Institute
Sponsored by: Dorcas and David Collins

Annette Kunkele, MD
University Hospital Berlin
Sponsored by: Linda Tonge

Shannon Maude, MD
Children's Hospital of Philadelphia

Stefani Spranger, PhD
University of Chicago
Sponsored by: Alex and Anne Ross

Blue Jean Ball 2018

Thank you to the Blue Jean Ball Chairs - Tricia Forbeck and Linda Tonge

Music donated by Jeff Trudell and Scott Kaufman

Wine Tasting presented by Terlato Wines

This event directly funds the Scholar Retreat

In Memory of

Henry G. Bates
Charlie Boehland
Kathleen Borman
Leroy Brownstein
Karen Estrada
Karen Fabiszak
Anthony G. Forbeck
Kevin P. Forbeck
William Guy Forbeck
Jane M. Frackelton
William H. Frackelton
Thomas Geldermann
Cyndi McKee Hinman
Mary Agnes Huber
Richard A. Kinzer
Dennis P. Lannert
Nora Cooney Marra
Richard J. Ring
Eunice Sherwood
Marilyn Singer
Glenn & Carol Solheim
John Tobin
Elizabeth Tobin
Thomas Ward
Donna Wehrenberg

In Honor of

Addison Collins
Georgia Collins
Kinzer Collins
David & Dorcas Collins
Jennifer Forbeck
The Forbeck Family
Chuck & Barbara Jesser
Rosandra Kaplan, MD

Thank you for your contribution and support in 2018! We look forward to reaching our new fundraising goal in 2019!

To make a contribution, please visit www.wgfrf.org/donate

Benefactors

Ms. Carylsue Ambel
Ms. Nancy Arango
Ms. Cheryl Linn Bailey
Mr. Michael Balestrieri
Mr. & Mrs. Peter Barnes
Mr. & Mrs. Timothy Black
Mrs. Ralph Bogan
Mr. & Mrs. John Bollero, Jr
Mrs. Jodi Boudart
Ms. Cheryl Brost
Mr. & Mrs. John Buchanan
Mr. & Mrs. Charles Carey
Mr. & Mrs. Frank Catalano
Mr. Jacob Chanson
Ms. Kate Cohen
Mr. & Mrs. David Collins
Ms. Meaghan Conniff
Mr. & Mrs. Edward Culbertson
Mr. & Mrs. Arvid Dahlstrom
Mr. William Divane
Mr. & Mrs. Richard Dousman
Mr. & Mrs. Charles Drawdy, Sr
Mr. Terrence Dunigan
Ms. Mary Dutta
Ms. Sara O Edwards
Mr. Bernard R Fabiszak
Mr. John B. Farley
Ms. Sharon Fiedler
Jack Fischer & Family
Mrs. Jennifer Forbeck
Mrs. Patricia Forbeck
Mr. & Mrs. FJ Frazier, III
Mrs. William Gage, Sr.
Ms. Jeannie Gallucci
Mr. & Mrs. Frank Gazzolo
Mrs. Thomas Geldermann
Mr. Matthew Gerdes
Mr. & Mrs. Eric Geschke
Mr. & Mrs. A. Nicholas Gianitsos
Drs. Inger & Craig Gibson
Mr. & Mrs. Hollis Griffin
Mrs. Melita Grunow
Mr. & Mrs. James Hanny
Mr. Clint Heine
Mr. Jay Hicks
Mr. & Mrs. Paul Hoffman
Mr. & Mrs. Eugene Holda
Ms. Edra Hollon
Mr. & Mrs. James Howard
Mr. & Mrs. Daniel Huber
Mrs. Al Huffman
Mr. & Mrs. Kevin Hull
Mr. Kinzer C. Jennings
Mr. & Mrs. Aaron Jesser
Mr. & Mrs. Charles Jesser
Ms. Sara Jesser
Mr. & Mrs. William Johnson
Mr. & Mrs. Gary Jouris
Mr. Patrick Joyce
Mr. Nikolas Kampton & Family
Mr. & Mrs. William Kasten
Mr. & Mrs. Joel Kennedy
Mr. William Kinzer
Kira Spedale Foundation
Mr. James A. Kirchschlager
Ms. Stacy Klein
Mr. Eric Kothanek
Mrs. Marie Kropp
Mr. & Mrs. Michael Kyle
Mr. & Mrs. Montague Laffitte
Mr. & Mrs. Andrew Laing
Mrs. Tobey Lannert
Ms. Ann Lehman
Mr. & Mrs. Craig Lindmark
Dr. Julie- Aurore Losman, MD PhD
Mr. Avery Pearce Lucas
Mr. & Mrs. George J. Ludington
Ms. Cindy Maher
Marshall Academy
McKee Family Foundation
Mr. & Mrs. Harris McMurry
Mr. & Mrs. Ronald Miller
Mrs. Robert Morava
Dr. Cynthia Morton, PhD
Mr. & Mrs. Mick & Nancy Neshek
Mr. Garrick Nielsen
Mr. & Mrs. John Notz
Mr. & Mrs. Roger O'Neill
Mr. Murray S Peretz
Ms. Anne Peterson
Mr. & Mrs. Richard Pfeil
Mrs. William Philipbar
Ms. Sally Prio
Dr. Kimryn Rathmell, MD PhD
Mrs. Frederick Reed
Drs. Leonard Reich
Mr. Matthew Richardson
Mr. & Mrs. Tom Rill
Mr. & Mrs. William Ring
Mrs. Mary Kay Ring
Ms. Mollie Ring
Robert & Patricia Moore Foundation
Mr. David Ross
Dr. Martine F. Roussel, PhD
Ms. Barbara Sander
Mr. & Mrs. Ken & Linda Schmidt
Mr. & Mrs Robert Schutz, Jr.
Ms. Rebecca A. Schutz
Ms. Francesca Sell
Dr. Jerry Shay, PhD
Mr. Craig Sherwood
Skinner Family Charitable Trust
Mrs. Robert Smyth
Ms. Holly Starck
Dr. Erica Lyn Stone, PhD
Mr. Seth R. Tannenbaum
Mr. & Mrs. Timothy Tobin
Mr. & Mrs. Stephen & Susan Tolbert
Dr. Kevin Tomera
Mr. Francesco Tommaso
Ms. Linda Tonge
Mr. & Mrs. William Turner
Mrs. Nancy Vaile
Mrs. John Volkhardt
Ms. Sally Ward & Family
Mrs. Lisa Warren
Ms. Jeannette Windon
Mr. & Mrs. Dave Wright
Mr. Bryan Wright
Ms. Lisa Wright
Mr. & Mrs. Alan Young

Donations and Sponsors

Blue Jean Ball Auction Donors

Mr. Jay Bauer
Big Mountain Brinery
Ms. Jodi Boudart
Bull Valley Golf Club
Ms. Addison Collins
Coopers Hawk Winery
Cornerstone Shop
Mrs. Jennifer Forbeck
Ms. Patricia Forbeck
Geneva National Resort
Mr. Matthew Gerdes
Mr. & Mrs. Inger Gibson
Gordy's Lakefront Marine
Green Bay Packers
Interstate Insurance Group, Inc
iPic Theaters
Dr. John Kemshead, PhD
Moretti's Ristorante & Pizzeria
Mr. Roger O'Neill
Picaboo.com
Ms. Lauren Roadman
Second City
The Abbey Resort
Ms. Linda Tonge

Retreat Sponsor

Mr. & Mrs. William Kasten
William Blair & Co.

Mentor Sponsor

CIBC Atlantic Trust
Dalco Metals, Inc
Mr. & Mrs. John Ring

Forum Sponsor

Wayne & Nan Kocourek Foundation
Kira Spedale Foundation

Sponsor a Scholar

Ms. Nancy Arango
Mr. Michael Balestrieri
The Bates Family
Big Foot Lions Club
Mr. & Mrs. David Collins
Ms. Ann Lehman
Mr. John O'Neill
Ross Family Foundation
Ms. Norine R. Smyth
Ms. Linda Tonge

Company Matching Donations

Aurora Health Care
Bank of America Charitable Foundation
Club General Motors
Palmetto State Bank

Golf Outing Donors

Brown's Service Wisconsin Golf
Bull Valley Golf Club
Geneva National Resort
Lakewood Golf Club

2019 Annual Golf Outing

Thank you to the Golf Outing Chairs - Ron Miller and Robert Schutz.

Course donated by Lakewood Golf Club.

This event directly funds the Scholar Retreat.

WILLIAM GUY FORBECK
RESEARCH FOUNDATION
wgfrf.org
CANCER'S LEADING THINKERS. TOGETHER IN ONE ROOM.

P.O. BOX 1033
CARBONDALE, COLORADO 81623

How You Can Help

To maximize our impact in the fight against cancer, we are expanding our calendar to six Forbeck Cancer Forums this year and eight in 2020. Help us increase our reach by donating to the Foundation, bringing a friend to an event or spreading the word about what we're up to on social media.

Facebook: https://www.facebook.com/wgfrf
LinkedIn: https://www.linkedin.com/company/wgfrf

Save the Date:

2019 Blue Jean Ball

Saturday, October 12th, 2019
6:00 PM – 10:00 PM

Pier 290
1 Liechty Drive
Williams Bay, WI

For more information and to purchase tickets, please visit wgfrf.org

Forbeck Cancer Forums accelerate progress in the fight against cancer by fostering a results driven exchange of ideas. Through intimate gatherings of the leading researchers, outside of conventional constraints and barriers, collaborations are formed that hasten cancer research.